Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Cancer Neurology

AstraZeneca’s OIC product clears efficacy hurdle

This article was originally published in Scrip

Executive Summary

AstraZeneca’s two Phase III trials of the pegylated peripherally acting mu opioid receptor antagonist naloxegol (pegylated naloxol) have hit their primary endpoints in patients with non-cancer related pain and opioid-induced constipation (OIC), top-line data show. But the good news for the product has been a little overshadowed by analysts’ fears over how high regulators will place the cardiovascular safety bar for drugs for this particular indication.

Table

View full table

Topics

Related Companies

Tags:
Gastrointestinal Cancer Neurology
Latest Headlines

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs

See All
UsernamePublicRestriction

Register

SC019425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By